Transforming the Perioperative Treatment Paradigm in Non-Metastatic RCC-A Possible Path Forward
{{output}}
In 2017, there is no adjuvant systemic therapy proven to increase overall survival in non-metastatic renal cell carcinoma (RCC). The anti-PD-1 antibody nivolumab improves overall survival in metastatic treatment refractory RCC and is generally tolerable. Mouse... ...
